Table 1.
Median-effect doses of TMZ and G47Δ in vitro*
| GSC line | ED50: drug or virus alone | |
| TMZ, μM | G47Δ, MOI | |
| GBM4 | 32 | 0.21 |
| GBM6 | 36 | 0.31 |
| GBM8 | 5.8 | 0.1 |
| GBM13 | 928 | 0.05 |
| GBM13 + BG | 325 | 0.05 |
| GBM13 + LM | 457 | 0.05 |
| BT74 | 1561 | 0.23 |
| BT74 + BG | 415 | 0.23 |
| BT74 + LM | 628 | 0.22 |
| HN | 1629 | 0.38 |
| HN +BG | 815 | 0.41 |
*
Sensitivity to TMZ was determined 5 days after adding TMZ. O6-methylguanine methyltransferase (MGMT)-positive GSCs (GBM13, BT74) and HN were also treated with O6-benzylguanine (BG) (50 μM) or lomeguatrib (LM) (20 μM) 2 hours before TMZ. Sensitivity to G47Δ was determined 4.5 days after infection. ED50 or Dm (dose required for 50% effect) values were determined from dose–response curves. GSC = glioblastoma stem cells; G47Δ = oncolytic herpes simplex virus; HN = human neurons; MOI = multiplicity of infection; TMZ = temozolomide.